Catherine A. Shu
YOU?
Author Swipe
View article: Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study Open
ClinicalTrials.gov Identifier: NCT04538664.
View article: The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer
The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer Open
Background 20% of patients with cancer are estimated to be ineligible for phase III trials because of restrictive eligibility criteria. Ineligibility rates for earlier phase trials are even greater. In response, several groups, including t…
View article: Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study Open
The safety profile was consistent with previous reports of amivantamab in EGFR-mutant NSCLC. Amivantamab demonstrated clinically meaningful and durable antitumor activity in participants with METex14 advanced NSCLC, including those who pro…
View article: Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late Metastases
Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late Metastases Open
Background/Objectives: While the genomic landscape of primary lung carcinomas is well characterized, there is a relative scarcity of fusion data on corresponding central nervous system (CNS) metastases. This study aimed to elucidate the mo…
View article: Challenges in Amplicon-Based DNA NGS Identification of MET Exon 14 Skipping Events in Non-Small Cell Lung Cancers
Challenges in Amplicon-Based DNA NGS Identification of MET Exon 14 Skipping Events in Non-Small Cell Lung Cancers Open
Introduction: MET Exon 14 skipping alterations are drivers of non-small cell lung carcinoma (NSCLC) with responses to tyrosine kinase inhibitors. Amplicon-based DNA NGS assays (DNA NGSs) for the detection of METex14 skipping can yield fals…
View article: Assessment of the hip-spine relationship in total hip arthroplasty for childhood hip disorders sequelae
Assessment of the hip-spine relationship in total hip arthroplasty for childhood hip disorders sequelae Open
In this article, we comment on the article by Oommen et al . Oommen et al provided a comprehensive overview of the management of hip centre restoration in total hip arthroplasty (THA) for childhood hip disorder sequelae. Given the developm…
View article: Deconstructing the Monolith: An Educational Module for Understanding Disparities Within Asian American, Native Hawaiian, and Pacific Islander Populations
Deconstructing the Monolith: An Educational Module for Understanding Disparities Within Asian American, Native Hawaiian, and Pacific Islander Populations Open
The AANHPI patient population comprises a myriad of different cultures, historical contexts, and health needs. We present an educational module that is associated with significant improvement of knowledge about health disparities specific …
View article: Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A Open
For patients with limited treatment options, amivantamab plus lazertinib demonstrated an antitumor activity with a safety profile characterized by EGFR- or MET-related adverse events, which were generally manageable.
View article: Weight loss in patients on osimertinib for metastatic <i>EGFR</i>-mutant non-small cell lung cancer
Weight loss in patients on osimertinib for metastatic <i>EGFR</i>-mutant non-small cell lung cancer Open
Background Cachexia is characterized by weight loss and decline in muscle mass and function and is a poor prognostic factor among patients with cancer. Patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) derive remarkab…
View article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings Open
Introduction Neoadjuvant chemoimmunotherapy has achieved overall survival (OS) benefit for patients with resectable non-small cell lung cancer (NSCLC). Here, we present outcomes after 3 years of follow-up from the first reported study of n…
View article: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Open
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity…
View article: A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve <i>EGFR</i> -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve <i>EGFR</i> -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial) Open
PURPOSE Preclinical studies demonstrated that dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways delay the emergence of resistance to EGFR tyrosine kinase inhibitors (TKIs), an…
View article: Table S2 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S2 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Prioritized drugs, prediction basis, and dosing schedule for PDX therapeutic study.
View article: Key Resources Table from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Key Resources Table from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Key Resources Table
View article: Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
View article: Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Detailed summary of drugs prioritized for testing in PDX models, based on rank of OncoTarget and OncoTreat predictions by –log10(Bonferroni p).
View article: Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain me…
View article: Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
View article: Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
View article: Table S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S6 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses o…
View article: Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S1 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
View article: Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NG…
View article: Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
View article: Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NG…
View article: Table S7 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
Table S7 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies Open
Current list of cancer cell lines with available drug perturbation RNASeq profiles, which together comprise the PanACEA resource.
View article: Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors …
View article: Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort A